Highlights

  • PolyNovo reported unaudited FY26 group revenue of $150 million, up 16.1% (20.3% in constant currency), with the full audited result including EBITDA and net profit due on 26 August 2026.
  • US commercial sales reached $102.1 million (up 15.6% reported, 21.1% in constant currency), while rest-of-world sales rose to $36.3 million.
  • Free cash flow swung to a positive $10.4 million from negative $10.1 million a year earlier, and cash on hand rose to $35.4 million.
  • Flagship NovoSorb BTM generated $125.8 million; the smaller NovoSorb MTX product nearly doubled to $12.6 million, with SynPath earmarked for an FY27 launch.
  • A new manufacturing facility has finished construction and is in validation, and the US sales force now exceeds 100 frontline staff.
  • A US pivotal burn trial funded by US agency BARDA has completed patient enrolment, keeping alive a potential FDA premarket approval pathway for full-thickness burns.

PolyNovo (ASX:PNV) has closed out its 2026 financial year with the kind of headline number long-term shareholders have been waiting for: group revenue of $150 million and, for the first time in years, positive free cash flow. The Melbourne-based medical-device maker, whose NovoSorb polymer technology is used to rebuild skin after severe burns and complex wounds, delivered the unaudited trading update in late July, roughly a month ahead of its audited full-year accounts. It arrives at a pivotal moment. New chief executive Bruce Peatey is barely half a year into the job, a long-serving chair has departed, a rebuilt manufacturing plant is nearing commissioning, and a US regulatory push years in the making is edging closer. The question for investors is whether this update marks a genuine inflection or simply another solid instalment.

A record top line, ahead of the audited numbers

PolyNovo's FY26 trading update, released in the final week of July 2026, is a preliminary, unaudited snapshot. Management confirmed group revenue of $150 million for the year to 30 June 2026, a 16.1% lift on the prior year, or 20.3% once the strength of the Australian dollar against the greenback is stripped out.

Commercial sales, which exclude items such as government stockpile orders and grant income, came in at $138.4 million, up 16.7%. The company also flagged a swing to positive free cash flow, a milestone that has eluded PolyNovo through much of its aggressive expansion phase.

Investors should note what the update does not yet contain. Headline profitability measures such as EBITDA and net profit after tax are scheduled for the audited full-year results on 26 August 2026. At the half-year mark, net profit was a razor-thin $3,000, so the audited FY26 bottom line remains the number to watch rather than assume.

From polymer chemistry to a global wound-care platform

PolyNovo commercialises NovoSorb, a proprietary biodegradable polyurethane platform developed with Australia's CSIRO. Its flagship product, NovoSorb BTM (Biodegradable Temporising Matrix), is a synthetic scaffold implanted into serious wounds. The body's own cells and blood vessels grow into the matrix, which then degrades, helping to regenerate a dermal layer before a skin graft is applied.

The core clinical use is full-thickness burns, trauma and complex surgical wounds where conventional dressings and grafts struggle. Around that flagship, PolyNovo has built a widening family: NovoSorb MTX, a more flexible matrix aimed at a broader range of wounds, and NovoSorb SynPath, which the company is preparing for an outpatient-focused launch in FY27.

The commercial engine is the United States, supported by a direct sales force the company says now exceeds 100 frontline personnel. Beyond the US, PolyNovo sells through its own operations in the United Kingdom, India, Hong Kong and Singapore, plus a network of distributors across additional markets.

Why this update matters

For a company that has spent heavily to build a US footprint, the significance of FY26 is less about the growth rate and more about the shape of the business. Double-digit revenue growth paired with positive free cash flow suggests the model is beginning to fund itself rather than lean on the balance sheet.

It also lands during a period of genuine boardroom change. Bruce Peatey took the chief executive role on 1 December 2025, following a stint by Dr Robyn Elliott as interim CEO. Peatey arrived from Dentsply Sirona, where he led an Americas division generating well over US$1 billion in annual revenue, and brings device-industry experience from Abbott, Baxter and Biosensors.

The leadership reset followed the departure of long-serving chair David Williams in October 2025 amid shareholder pushback, with Leon Hoare now in the chair. A cleaner cash-flow story gives the refreshed team a firmer platform from which to argue that the next growth phase is under control.

The financial and operational evidence

The regional split underlines how US-dependent PolyNovo remains. US commercial sales of $102.1 million grew 15.6% as reported, or 21.1% in constant currency, while rest-of-world sales reached $36.3 million, up 20.0% (21.9% in constant currency).

By product, NovoSorb BTM contributed $125.8 million, up 12.3% (16.4% constant currency), still the overwhelming majority of revenue. The younger NovoSorb MTX line jumped 89.6% to $12.6 million, evidence that portfolio diversification is starting to register even if off a small base.

On cash, operating cash flow of $24.0 million included a $3.5 million insurance recovery tied to a November 2025 fire at the company's research and development innovation centre. Free cash flow of $10.4 million reversed the prior year's $10.1 million outflow, and cash on hand rose modestly to $35.4 million at year-end.

Capacity is the other operational theme. A new manufacturing facility has completed construction and is in validation, with roughly $1.5 million of outstanding machinery spend expected in the first half of FY27. The company frames the plant as materially expanding capacity to meet rising demand.

Clinical pipeline and the US regulatory pathway

NovoSorb BTM is already cleared in the United States under the FDA's 510(k) route for wound management, and it is approved for full-thickness burns in a number of markets outside the US. The bigger prize is a US premarket approval (PMA) specifically for full-thickness burns, which would strengthen the product's standing in its foundational indication.

That effort runs through a pivotal clinical trial part-funded by BARDA, the US Biomedical Advanced Research and Development Authority, which historically committed non-dilutive support to the program. The trial has completed patient enrolment, comparing NovoSorb BTM against standard burn care across multiple centres.

Reported timelines have shifted, with a PMA submission understood to have moved towards late 2026. Investors should treat any regulatory date as a management target rather than a settled fact; PMA is a demanding pathway, and data analysis, filing and review all carry their own timelines and risks.

The addressable market

The commercial logic rests on the size and difficulty of the wounds PolyNovo addresses. Severe burns, trauma, necrotising infections and complex surgical defects are relatively low-volume but high-value cases, and management has consistently argued that BTM is expanding beyond large burns into a wider set of complex wound indications.

MTX and the planned SynPath launch are aimed at broadening the reach into less acute, outpatient settings, which is a far larger pool of patients. If PolyNovo can extend its technology from the burns unit into everyday wound care, the addressable opportunity grows well beyond its current footprint.

Reimbursement is the gatekeeper. The company has invested in US reimbursement and market-access capability precisely because coverage decisions, coding and hospital budgets ultimately determine how quickly a clinically strong product converts into sales.

Potential growth catalysts

Several identifiable catalysts could support the story from here. A successful PMA filing and, in time, approval for full-thickness burns would be the most strategically important. Commissioning of the new manufacturing facility could ease any capacity constraints as volumes rise.

The FY27 launch of SynPath, continued momentum in MTX, and deeper penetration of existing international markets each offer incremental upside. The audited full-year result in late August, with its first look at FY26 EBITDA and net profit, may also reset how the market frames the company's profitability.

None of these outcomes is guaranteed, and their timing is uncertain. They are best viewed as levers that could reignite growth if execution holds, not as events already banked.

Material risks and uncertainties

Concentration risk is front of mind. With the US generating the bulk of revenue and BTM dominating the product mix, any slowdown in either would weigh heavily. Currency movements also matter, as the gap between reported and constant-currency growth this year makes clear.

Regulatory and reimbursement risk is real. A PMA is not assured, timelines can slip, and coverage decisions can constrain uptake even for approved products. The November 2025 R&D facility fire is a reminder that operational disruptions can occur, with insurance recoveries still being finalised.

There is execution risk in a leadership transition, competitive pressure in wound care from larger device and biologics players, and the simple fact that a thin half-year profit means FY26 profitability has yet to be confirmed. PolyNovo also trades on growth expectations, so any disappointment can move the shares sharply.

A balanced outlook

The FY26 trading update reads as a step in the right direction rather than a transformation. Positive free cash flow, record revenue and a diversifying portfolio point to a maturing business, while the near-complete plant and enlarged sales force suggest the company is positioning for the next leg.

At the same time, the profit picture is unconfirmed until late August, the US regulatory catalyst remains a work in progress, and the business is still heavily reliant on one product in one market. Management has described PolyNovo as well positioned for continued sustainable growth in FY27, but pointedly did not issue specific guidance. Any external price targets circulating in the market are analyst opinions, not company forecasts, and should be treated accordingly.

For investors, the sensible frame is conditional. If PolyNovo converts its capacity, pipeline and regulatory work into sustained cash generation, the growth story could regain momentum; if execution or approvals stumble, the risks outlined above would come to the fore.

Conclusion

PolyNovo (ASX: PNV) enters FY27 with a record revenue base, its first positive free cash flow in years, a refreshed leadership team and a manufacturing upgrade nearing the finish line. The building blocks for reigniting its global growth story are visibly in place.

Whether they translate into durable, profitable expansion depends on the audited FY26 accounts due in late August, progress on the US burn approval, and the company's ability to broaden beyond its flagship product and its core US market. This update earns PolyNovo a closer look, but it is a milestone on a longer road rather than a destination, and nothing here should be read as advice to buy, hold or sell.